Breaking News Instant updates and real-time market news.

ARDX

Ardelyx

, BW

Babcock & Wilcox

$3.95

0.16 (4.22%)

17:28
10/11/17
10/11
17:28
10/11/17
17:28

On The Fly: After Hours Movers

HIGHER: Ardelyx (ARDX), up 33.3% after its tenapanor study hit its primary and secondary endpoints... Babcock & Wilcox (BW), up 9.6% after VIEX Capital Advisors reported a 6.4% stake in the company, saying the shares are undervalued... Sigma Designs (SIGM), up 3.8% after it announced major restructuring actions, including cutting 200-250 positions worldwide... XL Group (XL), up 3.2% after it said it sees net losses of $1.33B related to third quarter natural catastrophes... Herbalife (HLF), up 0.9% after Carl Icahn raised his firm's stake in the company to 26.2% due to the company's self tender offer. DOWN AFTER EARNINGS: Blackhawk (HAWK), down 7.2%. ALSO LOWER: J.Jill (JILL), down 37.6% after it cut its Q3 guidance... Protagonist Therapeutics (PTGX), down 11.9% after it filed to sell common stock... NanoString (NSTG), down 9.8% after it reported lower than expected preliminary revenue for Q3... Kandi Technologies (KNDI), down 5.5% after it filed a $300M mixed securities shelf... Juniper Networks (JNPR), down 3% after it lowered its Q3 guidance.

ARDX

Ardelyx

BW

Babcock & Wilcox

$3.95

0.16 (4.22%)

SIGM

Sigma Designs

$6.55

0.05 (0.77%)

XL

XL Group

$39.35

-0.32 (-0.81%)

HLF

Herbalife

$77.30

-0.4 (-0.51%)

HAWK

Blackhawk

$44.20

-0.4 (-0.90%)

JILL

J.Jill

$9.93

-0.22 (-2.17%)

PTGX

Protagonist Therapeutics

$19.81

0.14 (0.71%)

NSTG

NanoString

$15.66

0.02 (0.13%)

KNDI

Kandi Technologies

$8.25

-0.7 (-7.82%)

JNPR

Juniper

$26.86

-0.45 (-1.65%)

  • 11

    Oct

  • 11

    Oct

  • 11

    Oct

  • 12

    Oct

  • 18

    Oct

  • 19

    Oct

  • 24

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 12

    Oct

ARDX Ardelyx

05/15/17
WEDB
05/15/17
NO CHANGE
WEDB
Best Ideas List removals at Wedbush
Wedbush removed the following companies from its Best Ideas List, they are Ardelyx (ARDX), Builders FirstSource (BLDR), Covanta (CVA), Interpublic Group (IPG), lululemon (LULU), and Prosperity Bancshares (PB).
BW Babcock & Wilcox
$3.95

0.16 (4.22%)

03/03/17
UBSW
03/03/17
NO CHANGE
Target $14
UBSW
Buy
Babcock & Wilcox price target lowered to $14 from $20 at UBS
UBS analyst Steven Fisher lowered his price target on Babcock & Wilcox to $14 from $20 following Q4 results. The analyst called the quarter challenging as the company cited execution issues on a renewable plant in Europe. Fisher reduced his price target to reflect more debt on the balance sheet and a lower multiple. Fisher maintained his Buy rating on Babcock & Wilcox shares.
03/06/17
JRCO
03/06/17
DOWNGRADE
JRCO
Accumulate
Babcock & Wilcox downgraded to Accumulate from Buy at Johnson Rice
08/14/17
UBSW
08/14/17
DOWNGRADE
Target $3
UBSW
Neutral
Babcock & Wilcox downgraded to Neutral from Buy at UBS
UBS analyst Steven Fisher downgraded Babcock & Wilcox to Neutral citing lower earnings, ongoing project issues and more debt on the balance sheet following the company's Q2 results. The analyst cut his price target for the shares to $3 from $13.
08/14/17
08/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Babcock & Wilcox (BW) downgraded to Neutral from Buy at UBS with analyst Steven Fisher citing lower earnings, ongoing project issues and more debt on the balance sheet following the company's second quarter results. The analyst cut his price target for the shares to $3 from $13. 2. Summit Hotel Properties (INN) downgraded to Underperform from Buy at BofA/Merrill. 3. Pure Storage (PSTG) downgraded to Hold from Buy at Maxim with analyst Nehal Chokshi saying he believes Flash Blade's "lack of depth of data management features" presents risk to meeting guidance of accelerating year-over-year growth. 4. CNO Financial (CNO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Nigel Dally saying valuation is full with shares near all-time highs and has concerns about deteriorating sales and management's tempered expectations around ROE growth. 5. Acushnet Holdings (GOLF) downgraded on growth concerns at DA Davidson with analyst Andrew Bruns citing his increased caution on the growth outlook of its Club, FootJoy and Performance units. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SIGM Sigma Designs
$6.55

0.05 (0.77%)

10/14/16
BARD
10/14/16
NO CHANGE
Target $9
BARD
Outperform
Sigma Designs could be acquired over time, says Baird
Baird analyst Tristan Gerra met with Sigma Designs management and said Mobile T remains on track to ramp next year with overall IoT revenue also expected to benefit from multiple design wins. Gerra said he continues to believes Sigma Designs could be acquired over time given its strong IP. Gerra reiterated his Outperform rating and $9 price target on Sigma Designs shares.
06/07/17
BNCH
06/07/17
NO CHANGE
Target $10
BNCH
Buy
Sigma Designs could become 'prime acquisition target,' says Benchmark
Following Sigma Designs' (SIGM) report of mixed Q1 results, Benchmark analyst Gary Mobley contends investors care about two main things: growing IoT revenue, which is being seen, and an "outright divestiture" of SmartTV assets. If Sigma can shed assets and become a pure play IoT chip/cloud infrastructure company, Mobley believes it could become a "prime acquisition target" for a radio frequency IC company such as Silicon Laboratories (SLAB) or MaxLinear (MXL). If it is not acquired but can raise $100M by selling non-core, non-IoT businesses, Sigma could make additional acquisitions to bolster its IoT focus, said Mobley, who keeps a Buy rating and $10 price target on the stock.
12/07/16
LSCM
12/07/16
DOWNGRADE
LSCM
Hold
Sigma Designs downgraded to Hold from Buy at Lake Street
Lake Street analyst Jaeson Schmidt downgraded Sigma Designs to Hold and lowered its price target to $7 from $8.50 due to weak revenue guidance and price competitiveness of the market.
12/07/16
NEED
12/07/16
DOWNGRADE
NEED
Hold
Sigma Designs downgraded to Hold from Buy at Needham
XL XL Group
$39.35

-0.32 (-0.81%)

08/28/17
JPMS
08/28/17
NO CHANGE
JPMS
JPMorgan sees up to $20B of insured losses from Harvey
Harvey could result in $10B-$20B of industry insured losses making it one of the top 10 most costly hurricanes to hit the U.S., JPMorgan analyst Sarah DeWitt tells investors in a research note. The analyst lists Validus (VR), RenaissanceRe (RNR), Everest Re (RE), XL Group (XL), Arch Capital (ACGL), Travelers (TRV), Chubb (CB), Allstate (ALL) and Progressive (PGR) as the property casualty insurers with the most exposure to Texas hurricanes.
09/11/17
LEHM
09/11/17
NO CHANGE
LEHM
Irma and Harvey insured losses expected to top $100B, says Barclays
Barclays analyst Jay Gelb notes initial indications are Hurricane Irma's impact on Florida could result in insured losses of up to $60B. Irma will likely be the largest storm to ever impact the U.S., although not as bad as if Miami suffered a direct hit, Gelb tells investors in a research note on the insurance space titled "Devastating Irma Impact on Insurers, But It Could Have Been Worse." All in, Irma and Harvey insured losses are expected to exceed $100B, Gelb points out. He believes the re/insurance stocks could suffer from near-term uncertainty regarding the extent of losses. Of the names he covers, the analyst expects Everest Re (RE), XL Group (XL), RenaissanceRe (RNR), Validus (VR) and Aspen Insurance (AHL) "to take the brunt of Irma losses." Book value declines of more than 20% could require equity capital raises, Gelb contends. He says Chubb (CB), Travelers (TRV) and Hartford Financial (HIG) have relatively less exposure while AIG (AIG) could have greater losses among the primary insurers.
09/11/17
JPMS
09/11/17
NO CHANGE
JPMS
Irma losses could be lower than expected, says JPMorgan
JPMorgan analyst Sarah DeWitt believes losses from Hurricane Irma could be at the lower end of the $20B-$60B expected range since the storm weakened faster than expected. The analyst estimates the impact to book values for the companies she covers should be a "manageable" 1%-2%. Among the property casualty insurers, the analyst views Validus (VR), Everest Re (RE) and XL Group (XL) as the most oversold. She lists those three along with RenaissanceRe (RNR), Travelers (TRV), Arch Capital (ACGL), Chubb (CB), Allstate (ALL) and Progressive (PGR) as the P&C insurers with the most exposure to U.S. hurricanes.
09/11/17
BUCK
09/11/17
INITIATION
Target $42
BUCK
Neutral
XL Group initiated with a Neutral at Buckingham
Buckingham analyst Amit Kumar initiated XL Group with a Neutral and a $42 price target.
HLF Herbalife
$77.30

-0.4 (-0.51%)

08/02/17
SBSH
08/02/17
NO CHANGE
Target $72
SBSH
Neutral
Herbalife earnings beat on lower tax rate, says Citi
Citi analyst Beth Kite attributes Herbalife's better than expected Q2 earnings to a lower tax rate. The analyst raised her 2017 earnings per share estimate to $4.70 from $4.62 but lowered her 2018 estimate to $4.98 from $5.15. Kite has concerns over the impact of the FTC Consent Order in the U.S., Nutrition Club dynamics and social media pressures in China as well as the distributor sponsorship in Mexico. She lowered her price target for Herbalife shares to $72 from $74 and keeps a Neutral rating on the shares.
10/03/17
PIVT
10/03/17
NO CHANGE
Target $120
PIVT
Buy
Herbalife estimates lowered on share repurchase challenges at Pivotal Research
Pivotal analyst Timothy Ramey lowered his Q4 and 2018 estimates for Herbalife as he now believes the company's and his own share repurchase forecasts "are not attainable." Ramey added that "is bizarre that the company was so singularly unsuccessful at share repurchase to not even spend its cash flow this year," but he hopes the company's Dutch Auction is successful and allows for some progress on retiring shares. He keeps a Buy rating and $120 price target on Herbalife shares.
08/03/17
TIGR
08/03/17
NO CHANGE
TIGR
Buy
Herbalife's 2017 remains a transition year, says Tigress Financial
In a post-earnings research note, Tigress Financial analyst Ivan Feinseth believes 2017 remains a transition year for Herbalife. He expects the company's business to show positive acceleration as management continues to implement new initiatives to drive growth. He reiterates a Buy rating on the shares.
10/03/17
SBSH
10/03/17
NO CHANGE
Target $73
SBSH
Neutral
Citi still cautious on Herbalife after updated Q3 outlook
Citi analyst Beth Kite says Herbalife's initial Q3 guidance offered sales growth as expected and higher earnings on a lower tax rate. The analyst notes her investment thesis remains focused on local currency sales growth. As such, last night's updated guidance keeps unchanged Kite's "cautious position on the shares." She raised her price target for Herbalife to $73 from $71 and keeps a Neutral rating on the name.
HAWK Blackhawk
$44.20

-0.4 (-0.90%)

08/21/17
CHLM
08/21/17
NO CHANGE
CHLM
Vantiv, PayPal could be $100 stocks by 2020, says Craig-Hallum
Craig-Hallum analyst Brad Berning notes that PayPal (PYPL) and Vantiv (VNTV) are two different business models that are both winning market share within the global secular growth of payments converting to digital from cash and check. The analyst believes both companies could be $100 stocks by 2020. Berning is also adding Blackhawk (HAWK) to his near-term risk/reward list, removing Vantiv and keeping PayPal, LendingClub (LC) and BofI Holding (BOFI).
09/01/17
CHLM
09/01/17
NO CHANGE
Target $58
CHLM
Buy
Blackhawk target raised to $58 on CashStar deal at Craig-Hallum
Craig-Hallum analyst Bradley Berning raised his price target for Blackhawk Network Holdings to $58 from $58 to reflect accretion from the CashStar acquisition. The deal should be a positive catalyst for the shares and makes strategic sense, Berning tells investors in a research note. He keeps a Buy rating on Blackhawk.
09/12/17
BMOC
09/12/17
NO CHANGE
BMOC
Blackhawk acquisition positive, says BMO Capital
BMO Capital analyst Paulo Ribeiro is upbeat on Blackhawk's acquisition of CashStar.The analyst says that the deal expands Blackhawk's digital capabilities and greatly increases its total available market. He estimates that the deal is 3.2% accretive in fiscal 2018 and 5.7% accretive in fiscal 2019. He keeps an Outperform rating on the shares.
10/10/17
CHLM
10/10/17
NO CHANGE
CHLM
Green Dot, CPI Card added to Favorite Near-Term Risk/Reward List at Craig-Hallum
Craig-Hallum analyst Brad Berning added Green Dot (GDOT) and CPI Card Group (PMTS) to his Favorite Near-Term Risk/Reward List, saying he expects the former's positive momentum and estimate revisions to continue while believing the current quarter and 4Q outlook can be a positive catalyst for the latter. The analyst also sees positive near-term catalysts for Blackhawk (HAWK), LendingClub (LC), Verifone (PAY) and BofI Holding (BOFI).
JILL J.Jill
$9.93

-0.22 (-2.17%)

08/29/17
BOFA
08/29/17
NO CHANGE
BOFA
J.Jill shares defended at BofA/Merrill
08/30/17
MSCO
08/30/17
NO CHANGE
Target $15
MSCO
Overweight
J.Jill post-earnings pullback overdone, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said J.Jill's high-single-digit comp growth and over 20% earnings growth are "best in class" and she believes the stock's pullback after the company's earnings report was overdone. The company's clean inventory exiting the quarter should bode well for Q3 gross margins, added Greenberger, who keeps an Overweight rating and $15 price target on J.Jill shares.
08/30/17
RHCO
08/30/17
NO CHANGE
RHCO
Concerns about J.Jill gross margin overdone, says SunTrust
After J. Jill disclosed that its gross margins fell last quarter, SunTrust analyst Pamela Quintiliano blames the decline on a tough comp and "a soft response" to the company's online offerings. However, the analyst says that demand for the company's full priced products improved in July, while its overall fundamentals remain intact. The analyst thinks that concerns about the gross margins were overdone and that the weakness in the stock has created a buying opportunity.
04/03/17
04/03/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. J.Jill (JILL) was initiated with a Buy at UBS, BofA/Merrill, SunTrust, Jefferies, and Deutsche Bank, J.Jill was initiated with an Overweight at Morgan Stanley, with a Market Perform at Wells Fargo, an Outperform at Cowen, and a Neutral at Macquarie. 2. Snap (SNAP) initiated with a Hold at Argus. 3. Ctrip.com (CTRP) initiated with an Outperform at Cowen. 4. MasTec (MTZ) initiated with a Neutral at Credit Suisse. 5. Physicians Realty Trust (DOC) initiated with an Outperform at FBR Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PTGX Protagonist Therapeutics
$19.81

0.14 (0.71%)

05/30/17
BMOC
05/30/17
NO CHANGE
Target $45
BMOC
Outperform
Protagonist Therapeutics price target raised to $45 on licensing at BMO Capital
BMO Capital analyst Ian Somaiya raised Protagonist Therapeutics' price target to $45 from $34 and reiterated his Overweight rating citing the PGG-200 licensing deal with Janssen. The analyst said the deal increases the probability of clinical and regulatory success in Crohn's and ulcerative colitis and likely reduces the need for future financings.
07/21/17
BTIG
07/21/17
INITIATION
BTIG
Buy
Protagonist Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started coverage of Protagonist with a $36 price target and a Buy rating. The analyst says that the company's oral peptide technology platform "shows promise for treating inflammatory bowel disease." He says that the mechanisms of action of two of the company's drugs "have already been clinically validated by approved treatments for patients that have not adequately responded to TNF-blockers and other existing treatments ."
06/01/17
LEER
06/01/17
NO CHANGE
Target $35
LEER
Outperform
Protagonist Therapeutics price target raised to $35 from $29 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Protagonist Therapeutics to $35 citing the "attractive" partnership for PTG-200. The analyst reiterates an Outperform rating on the shares.
05/31/17
BMOC
05/31/17
NO CHANGE
BMOC
Protagonist Therapeutics price target raised to $45 from $34 at BMO Capital
BMO Capital analyst M. Ian Somaiya increased his price target on Protagonist (PTGX) after the company reached a licensing deal with Johnson & Johnson (JNJ) for its PTG-200 drug. The analyst says that the deal increases the drug's chances of success , and he calls J&J "an ideal partner." Somaiya keeps an Outperform rating on the stock.
NSTG NanoString
$15.66

0.02 (0.13%)

04/20/17
04/20/17
DOWNGRADE
Target $20

Equal Weight
NanoString downgraded on cautious survey results at Morgan Stanley
As previously reported, Morgan Stanley downgraded NanoString to Equal Weight from Overweight and lowered its price target to $20 from $23. Analyst Steve Beuchaw said expectations appear high relative to his instrument and CDx survey. The survey indicates muted expectations for instrument demand and industry discussions suggest less enthusiasm for the nCounter instrument for diagnostic applications. Beuchaw now expects growth to be 20-30% over the next three years compared to 30-40% growth over the last two years and lowered estimates and reduced his price target to $20 from $23 on shares.
04/20/17
MSCO
04/20/17
DOWNGRADE
MSCO
Equal Weight
NanoString downgraded to Equal Weight from Overweight at Morgan Stanley
01/20/17
COWN
01/20/17
NO CHANGE
Target $25
COWN
Outperform
NanoString price target lowered to $25 from $30 at Cowen
Cowen analyst Doug Schenkel lowered his price target on NanoString to $25 and cut his forecast to reflect the impact of its Q4 miss and lingering uncertainty. Despite the shortfall, Schenkel still believes in the company's platform and views the recent selloff as disproportionate. He believes better execution will drive the shares higher and said the company remains attractive as a standalone and strategic asset. Schenkel maintained his Outperform rating on NanoString shares.
12/06/16
BARD
12/06/16
NO CHANGE
Target $26
BARD
Outperform
NanoString a top growth idea, says Baird
Baird analyst Catherine Ramsay is recommending NanoString as a top idea after hosting management meetings. The analyst said its core business seems healthy, with SPRINT systems driving continued installed base growth, and meaningful upside is seen from companion diagnostic collaborations. Ramsay said shares are undervalued relative to its growth profile and upside potential. Ramsay reiterated her Outperform rating and $26 price target on NanoString shares.
KNDI Kandi Technologies
$8.25

-0.7 (-7.82%)

01/25/17
01/25/17
NO CHANGE

Kandi Technologies mentioned cautiously at Geo Investing
JNPR Juniper
$26.86

-0.45 (-1.65%)

09/12/17
NEED
09/12/17
NO CHANGE
NEED
Gigamon outlook positive, shares could reach $55-$60, says Needham
After media outlets reported that Elliott Management's private equity arm had submitted a bid to acquire Gigamon (GIMO), Needham analyst Alex Henderson believes that there are "three likely outcomes" to the situation: Gigamon will be acquired by private equity firms for $50+; Gigamon becomes a takeover target for strategic players such as F5 (FFIV), Oracle (ORCL), HP (HPE), and Juniper (JNPR);, or the company reports strong Q3 and Q4 results and the stock rallies. The analyst says that the stock could reach $55-$60 if a bidding war materializes. He reiterates a $50 price target and a Buy rating on the shares.
07/21/17
07/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Capital One (COF) upgraded to Perform from Underperform at Oppenheimer with analyst Ben Chittenden saying the second quarter results point to signs of credit stabilization. 2. Juniper (JNPR) upgraded to Outperform from Market Perform at Raymond James with analyst Simon Leopold citing favorable risk/reward and an underappreciated "pivot" in the business. 3. CalAtlantic (CAA) upgraded to Outperform from Market Perform at JMP Securities with analyst Peter Martin saying he is increasingly optimistic that the stock can rise in 2018. 4. Total (TOT) upgraded to Buy from Hold at Canaccord. 5. SK Telecom (SKM) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/17
NOMU
10/06/17
NO CHANGE
Target $275
NOMU
Buy
Nomura Instinet lays out potential takeover targets for Broadcom
With revenues this year on track to reach $17B, few opportunities in the semiconductor space exist that would move the needle for Broadcom Limited (AVGO), Nomura Instinet analyst Romit Shah tells investors in a research note. As a result, the analyst believes the company could be looking to acquire companies in peripheral spaces. Shah's analysis yields CA Technologies (CA), NetApp (NTAP), Juniper (JNPR), Garmin (GRMN), Trimble (TRMB), Akamai (AKAM), F5 Networks (FFIV), Ciena (CIEN) and EchoStar (SATS) as possible takeover targets. The analyst thinks Broadcom shares may continue to "languish" in the near term given uncertainty with the Brocade acquisition and iPhone supply constraints. Shah, however, remains optimistic in Broadcom's ability to generate $20-plus in earnings per share in the future. He keeps a Buy rating on the shares with a $275 price target.
10/11/17
BOFA
10/11/17
DOWNGRADE
Target $31
BOFA
Neutral
Juniper downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Tal Liani downgraded Juniper to Neutral and cut its price target to $31 from $35. The analyst maintains a positive bias on shares but sees more balanced risk/reward given a mix of tough comps, potential weaker carrier capex environment, and limited margin upside. Liani sees no clear positive catalysts for significant outperformance but notes a cash repatriation holiday would be a positive event.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.